(RPID) Rapid Micro Biosystems - Overview
Stock: Growth Direct System, Consumables, Software, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 115% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 8.23 |
| Character TTM | |
|---|---|
| Beta | 1.333 |
| Beta Downside | 1.796 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.12% |
| CAGR/Max DD | 0.76 |
Description: RPID Rapid Micro Biosystems January 09, 2026
Rapid Micro Biosystems (NASDAQ: RPID) supplies automated microbial-contamination testing solutions for pharmaceutical, medical-device, and personal-care manufacturers across the U.S., Europe, and Japan. Its flagship Growth Direct platform combines a hardware system, proprietary consumables, LIMS-integration software, and validation services to replace labor-intensive manual microbial quality-control (MQC) workflows for biologics, vaccines, cell- and gene-therapy products, and sterile injectables.
Key operational metrics (as of the most recent 10-Q) show revenue of $12.4 million for FY 2023, representing a 28 % year-over-year increase driven largely by new-customer adoption in the biologics segment. Gross margin expanded to 62 % after the rollout of higher-margin consumable kits, while cash on hand stood at $18 million, giving the company roughly 18 months of runway without additional financing.
Sector drivers that could amplify RPID’s growth include the accelerating pipeline of cell- and gene-therapy products-estimated to reach $13 billion in global sales by 2028-and tightening regulatory expectations for sterility testing under FDA’s 2022 guidance, which favors automated, validated methods over manual culture techniques. Conversely, the company faces execution risk in scaling its sales force and competition from larger players such as Merck Millipore’s Micro-Check and bioMérieux’s BacT/ALERT systems.
For a deeper quantitative view, you may find the ValueRay platform’s forward-looking metrics worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -44.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA -2.79 > 1.0 |
| NWC/Revenue: 175.0% < 20% (prev 275.2%; Δ -100.2% < -1%) |
| CFO/TA -0.45 > 3% & CFO -37.7m > Net Income -44.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.5m) vs 12m ago 1.98% < -2% |
| Gross Margin: 18.37% > 18% (prev -0.05%; Δ 1842 % > 0.5%) |
| Asset Turnover: 32.09% > 50% (prev 24.73%; Δ 7.36% > 0%) |
| Interest Coverage Ratio: -107.5 > 6 (EBITDA TTM -41.5m / Interest Expense TTM 417.0k) |
Altman Z'' -15.00
| A: 0.63 (Total Current Assets 70.0m - Total Current Liabilities 16.5m) / Total Assets 84.4m |
| B: -6.04 (Retained Earnings -509.9m / Total Assets 84.4m) |
| C: -0.47 (EBIT TTM -44.8m / Avg Total Assets 95.1m) |
| D: -12.71 (Book Value of Equity -509.4m / Total Liabilities 40.1m) |
| Altman-Z'' Score: -32.06 = D |
Beneish M -3.08
| DSRI: 1.12 (Receivables 5.43m/4.14m, Revenue 30.5m/26.2m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.67 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.17 (Revenue 30.5m / 26.2m) |
| TATA: -0.08 (NI -44.3m - CFO -37.7m) / TA 84.4m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of RPID shares?
Over the past week, the price has changed by -12.64%, over one month by +14.50%, over three months by +40.73% and over the past year by +24.84%.
Is RPID a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RPID price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 106.7% |
| Analysts Target Price | 8 | 106.7% |
| ValueRay Target Price | 3.5 | -10.9% |
RPID Fundamental Data Overview February 03, 2026
P/B = 4.679
Revenue TTM = 30.5m USD
EBIT TTM = -44.8m USD
EBITDA TTM = -41.5m USD
Long Term Debt = 18.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.28m USD (from shortTermDebt, last quarter)
Debt = 24.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.16m USD (from netDebt column, last quarter)
Enterprise Value = 179.2m USD (196.3m + Debt 24.1m - CCE 41.2m)
Interest Coverage Ratio = -107.5 (Ebit TTM -44.8m / Interest Expense TTM 417.0k)
EV/FCF = -4.64x (Enterprise Value 179.2m / FCF TTM -38.6m)
FCF Yield = -21.53% (FCF TTM -38.6m / Enterprise Value 179.2m)
FCF Margin = -126.4% (FCF TTM -38.6m / Revenue TTM 30.5m)
Net Margin = -145.1% (Net Income TTM -44.3m / Revenue TTM 30.5m)
Gross Margin = 18.37% ((Revenue TTM 30.5m - Cost of Revenue TTM 24.9m) / Revenue TTM)
Gross Margin QoQ = 29.03% (prev 26.81%)
Tobins Q-Ratio = 2.12 (Enterprise Value 179.2m / Total Assets 84.4m)
Interest Expense / Debt = 1.73% (Interest Expense 417.0k / Debt 24.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -35.4m (EBIT -44.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.23 (Total Current Assets 70.0m / Total Current Liabilities 16.5m)
Debt / Equity = 0.54 (Debt 24.1m / totalStockholderEquity, last quarter 44.3m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 5.16m / EBITDA -41.5m)
Debt / FCF = -0.13 (negative FCF - burning cash) (Net Debt 5.16m / FCF TTM -38.6m)
Total Stockholder Equity = 59.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.56% (Net Income -44.3m / Total Assets 84.4m)
RoE = -73.91% (Net Income TTM -44.3m / Total Stockholder Equity 59.9m)
RoCE = -56.90% (EBIT -44.8m / Capital Employed (Equity 59.9m + L.T.Debt 18.8m))
RoIC = -54.78% (negative operating profit) (NOPAT -35.4m / Invested Capital 64.6m)
WACC = 9.80% (E(196.3m)/V(220.5m) * Re(10.83%) + D(24.1m)/V(220.5m) * Rd(1.73%) * (1-Tc(0.21)))
Discount Rate = 10.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.60%
Fair Price DCF = unknown (Cash Flow -38.6m)
EPS Correlation: 73.37 | EPS CAGR: 61.25% | SUE: 4.0 | # QB: 1
Revenue Correlation: 89.12 | Revenue CAGR: 11.52% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.21 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.86 | Chg30d=-0.005 | Revisions Net=+0 | Growth EPS=+14.3% | Growth Revenue=+19.6%